Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15617943 | 1.00 | MAPK1 (0.36) | MAPK1MEN1KMT2AEPHX2CHRM2 | |
| SCHEMBL18743086 | 1.00 | MAPK1 (0.36) | MAPK1MEN1KMT2AEPHX2CHRM2 | |
| SCHEMBL15423567 | 0.80 | MAPK1 (0.37) | MAPK1MEN1KMT2AEPHX2CHRM2 | |
| SCHEMBL4748069 | 0.79 | MAPK1 (0.32) | MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL29188007 | 0.76 | NR1H2 (0.39) | MAPK1MEN1KMT2AEPHX2CHRM2 | |
| SCHEMBL30158886 | 0.76 | MEN1 (0.31) | MAPK1MEN1KMT2A | |
| SCHEMBL30158900 | 0.76 | NR1H2 (0.39) | MAPK1MEN1KMT2AEPHX2CHRM2 | |
| SCHEMBL12033287 | 0.76 | NR1H2 (0.33) | MAPK1MEN1KMT2AEPHX2CHRM2 | |
| SCHEMBL29188005 | 0.76 | NR1H2 (0.39) | MAPK1MEN1KMT2AEPHX2CHRM2 | |
| SCHEMBL13330148 | 0.76 | NR1H2 (0.33) | MAPK1MEN1KMT2AEPHX2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9655944-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160361375-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2016-12-15 | — | — | US | disclosed |
| US-9296782-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150175655-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2015-06-25 | — | — | US | disclosed |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2014-01-16 | — | — | US | disclosed |
| EP-1179750-B1 | Positive photosensitive composition and method for producing a precision integrated circuit element using the same | FUJIFILM CORP (JP) | 2012-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175655-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | MAPK1 3693/4885MEN1 3724/4885KMT2A 4659/4885 |
| US-20160361375-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | MAPK1 3681/4885MEN1 3419/4885KMT2A 4606/4885 |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | MAPK1 3681/4885MEN1 3419/4885KMT2A 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.